 Home > Biochemistry News > Biotechnology News > Significantly relieve the symptoms of advanced DMD patients with phase 2 clinical results positive

Significantly relieve the symptoms of advanced DMD patients with phase 2 clinical results positive

 Last Update: 2021-09-28
 Source: Internet
 Author: User

Tags

scalpel picture

positive elisa test

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 24, 2021, Capricor Therapeutics announced the final results of a phase 2 clinical trial of cell therapy CAP-1002 for the treatment of patients with advanced Duchenne muscular dystrophy (DMD)

Duchenne muscular dystrophy is a rare and fatal genetic disease

CAP-1002 is an allogeneic cell therapy.

▲Introduction of CAP-1002 (picture source: Capricor Therapeutics official website)

This trial was conducted in patients with advanced DMD disease.

The final data analysis showed that after receiving 4 CAP-1002 treatments for 1 year, the upper limb function test index (PUL v1.

The specific results of the test are shown in the following table:

Picture source: reference [1]

Reference materials:

[1] Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express significantly relieves the symptoms of advanced DMD patients, and the Phase 2 clinical results of cell therapy are positive

09-30

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Significantly relieve the symptoms of advanced DMD patients with phase 2 clinical results positive

Related Articles

Express significantly relieves the symptoms of advanced DMD patients, and the Phase 2 clinical results of cell therapy are positive